Generic Engineering Construction and Projects Limited
NSE: GENCON | Information Technology
Market Fundamentals
Stock Intelligence & News
PI Industries’ weak core business keeps investors on edge
Falling demand, generic competition in a key molecule and weak customer ordering trends continue to weigh on PI Industries’ CSM business, raising questions over the pace of recovery in FY27.
Read Full Analysis →Lasa Supergenerics Limited
Lasa Supergenerics Limited has informed the Exchange about Board Meeting to be held on 29-May-2026 to inter-alia consider and approve the Audited Financial results of the Company for the Yearly ended March 2026 . |SUBJECT: Board Meeting Intimation
Read Full Analysis →Lasa Supergenerics Limited
Financial Results |Meeting Date: 29-May-2026
Read Full Analysis →AI-Powered Alerts for Your Portfolio
Alerfo's AI classifies every news event by type, severity, and market impact — then instantly notifies you via Email & WhatsApp only for the stocks you track.
Lasa Supergenerics Limited
Board Meeting Intimation |Meeting Date: 29-May-2026
Read Full Analysis →US drugs site TrumpRx to list 600 generics as Trump targets lower prices
US drugs site TrumpRx to list 600 generics as Trump targets lower prices
Read Full Analysis →Japan’s Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds
Japan’s Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds
Read Full Analysis →Goldman Sees Limited Upside for Dr. Reddy’s Laboratories Limited (RDY) Amid Generic Drug Concerns
Goldman Sees Limited Upside for Dr. Reddy’s Laboratories Limited (RDY) Amid Generic Drug Concerns
Read Full Analysis →Biocon reports 63% YoY fall in Q4 profit, final dividend of Rs. 0.50 recommended
Biocon's fourth-quarter net profit saw a significant drop of 63 percent year-on-year. This decline was attributed to exceptional charges impacting the company's financials. However, core businesses demonstrated growth. The company successfully integrated its biosimilars and generics operations. This strategic move aims to enhance scale and market reach. Biocon is now focused on improving profitability and creating long-term value for shareholders.
Read Full Analysis →Biocon Shares Rally Despite Net Profit Falling Over 60% In Q4 Earnings — Here's Why
Although the profitability dipped considerably in Q4, it was largely due to a high base effect, as Q4FY25 had benefitted fromelevated generic lenalidomide sales.
Read Full Analysis →Biocon Q4 Results: Net Profit Plunges 63% On High Base, Exceptional Item
The sharp decline in profit was largely a function of a high base effect, as Q4FY25 had benefitted from elevated genericlenalidomide sales and the impact of an exceptional in the current quarter.
Read Full Analysis →Get instant alerts when GENCON breaks news
Join investors who track Generic Engineering Construction and Projects Limited on Alerfo — free plan available.
Set Free Alert →Frequently Asked Questions
What is the current trend for GENCON?
GENCON is currently showing a volatility profile consistent with its sector peers, with sentiment being actively monitored by Alerfo news scanners.
How can I set alerts for Generic Engineering Construction and Projects Limited?
You can set real-time price and news alerts by registering on the Alerfo platform and adding GENCON to your custom watchlist.